Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

NCT03349177 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Pathological Complete Response
Neoadjuvant Chemotherapy

Interventions

DRUG: Epirubicin
DRUG: Fluorouracil
DRUG: Docetaxel
DRUG: Cyclophosphamide

Sponsor

Zhiyong Yu